Abstract: The present invention relates to an extracellular vesicle expressing a cytokine and an antibody, a method for producing same, and a use thereof. The present invention provides a method for producing an immune cell expressing both a cytokine and an antibody on membrane surface by transforming them with a first vector encoding a cytokine and a second vector encoding an antibody, and producing their extracellular vesicle expressing both a cytokine and an antibody on the surface. The present invention provides the extracellular vesicle which induces a desired cytokine response in cells that can be targeted with a specific antibody and is safe for the human body while exhibiting excellent anticancer effects. The present invention provides a new cancer treatment means that deliver drugs or physiologically active substances to specific cancer cells by loading a drug or physiologically active substance that exhibits a therapeutic effect on cancer in the extracellular vesicle.

Abstract: The present invention relates to a GFRAL-antagonistic antibody having improved affinity and a use thereof, and more particularly, the present invention relates to an anti-GFRAL antibody having improved affinity, comprising a heavy chain CDR and a light chain CDR of specific sequences, or an antigen-binding fragment thereof. The anti-GFRAL antibody having improved affinity exhibits higher binding ability to a GFRAL protein than a conventional anti-GFRAL antibody, and thus is expected to be effectively used for improving or treating cancer-related anorexia or cachexia syndrome and side effects of chemotherapy anticancer drugs.

Abstract: The present invention relates to a novel anti-C-MPL antibody and a use thereof, and specifically, to an anti-C-MPL antibody having an effect of increasing platelet production and its number through the maturation of megakaryocytes in the bone marrow, and a use thereof. The novel anti-C-MPL antibody (2R13) of the present invention is a polymer material and has a longer half-life than the conventional therapeutic agents, and it has the advantage of low self-antibody production and low immunogenicity as an antibody agent. In addition, it can be used as a therapeutic agent for thrombocytopenia by increasing the platelet level of patients suffering from chronic or complication-induced immune thrombocytopenia.

Abstract: The present invention relates to a method for screening a cytokine having anticancer activity that inhibits the exosome secretion or suppresses the expression of PD-L1, wherein a vector composed of gene encoding cytokine, linker domain, and transmembrane domain transforms into cancer cells, and cytokine exhibiting anticancer activity can be selected, and thus the selected cytokine is provided as a new anticancer agent. In addition, the present invention relates to composition for preventing or treating cancer diseases, the composition comprising IL-15, selected using the above-mentioned screening technique, or expression promoter or activator thereof as an active ingredient. In the present invention, it was found that treating cancer cells with IL-15 suppresses exosome secretion and the expression of PD-L1, and it was also found that the anticancer effect is directly exhibited on the cancer cells. Therefore, IL-15 or expression promoter or activator can be effectively used to prevent or treat cancer diseases.

Abstract: The present invention relates to a GFRAL-antagonistic antibody and a use thereof, and more particularly, to an anti-GFRAL antibody comprising a heavy chain CDR and a light chain CDR of specific sequences, and an antigen-binding fragment thereof. The anti-GFRAL antibody is expected to be usefully utilized for ameliorating or treating anorexia-cachexia syndrome associated with cancer, and adverse effects of chemotherapeutic drugs.

Abstract: The present invention relates to cytokine-based immune cells and an immunotherapeutic use thereof, and an immune cell according to an aspect is designed in such a form that a cytokine is linked to the surface of the cell via a linker, and thus the cytokine continuously stimulates the immune cell, thereby inducing proliferation and activation, and the cytokine does not affect surrounding cells, whereby side effects can be minimized.

Abstract: The present invention relates to a cytokine fusion polypeptide or a cytokine library comprising the same, and according to the cytokine fusion polypeptide or a cytokine library comprising the same according to an aspect, it enables continuous stimulation by a cytokine to a target cell and thus can easily and accurately evaluate the functionality of cytokines at the single cell level.

Abstract: The present invention relates to an glucose uptake modulator, a pharmaceutical composition comprising the glucose uptake modulator, and a method of treating a diabetes or diabetic complications in a mammal in need thereof, which comprises administering to said mammal an effecting amount of a glucose uptake modulator.

Abstract: The present inventors show that a brief exposure to EGF stimulates insulin secretion glucose-independently via a Ca2+ influx- and PLD2-dependent mechanism. Furthermore, the present invention shows that EGF is a novel secretagogue that lowers plasma glucose levels in normal and diabetic mice, suggesting the potential for EGF treatment in diabetes.

Abstract: The present invention relates to an glucose uptake modulator, a pharmaceutical composition comprising the glucose uptake modulator, and a method of treating a diabetes or diabetic complications in a mammal in need thereof, which comprises administering to said mammal an effecting amount of a glucose uptake modulator.